Toward a new era in cancer treatment: Message from the new editor-in-chief

摘要

I am honored for the opportunity to lead the journal and build upon the strong success of the past decade under the founding Editor-in-Chief, Dr. Dan Von Hoff, his Deputy and Senior Editors, and the Editorial Board. Since its launch in late 2001, Molecular Cancer Therapeutics (MCT) has grown in stature, impact, and respect among cancer researchers interested in experimental therapeutics discovery and preclinical development. With a focus on preclinical studies of cancer therapeutics, the journal has been and will continue to be nicely positioned between AACR's 2 broad-based publications, Cancer Research, which focuses on basic mechanisms of cancer biology, and Clinical Cancer Research, which focuses on clinical and translational research.